Imperial College London
Portrait Picture

ProfessorMichaelLevin

Faculty of Medicine, Department of Infectious Disease

Chair in Paediatrics & International Child Health
 
 
 
//

Contact

 

+44 (0)20 7594 3760m.levin Website

 
 
//

Location

 

233Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kaufmann:2017:10.3389/fimmu.2017.01203,
author = {Kaufmann, SHE and Dockrell, HM and Drager, N and Ho, MM and McShane, H and Neyrolles, O and Ottenhoff, THM and Patel, B and Roordink, D and Spertini, F and Stenger, S and Thole, J and Verreck, FAW and Williams, A},
doi = {10.3389/fimmu.2017.01203},
journal = {Frontiers in Immunology},
title = {TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development},
url = {http://dx.doi.org/10.3389/fimmu.2017.01203},
volume = {8},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
AU  - Kaufmann,SHE
AU  - Dockrell,HM
AU  - Drager,N
AU  - Ho,MM
AU  - McShane,H
AU  - Neyrolles,O
AU  - Ottenhoff,THM
AU  - Patel,B
AU  - Roordink,D
AU  - Spertini,F
AU  - Stenger,S
AU  - Thole,J
AU  - Verreck,FAW
AU  - Williams,A
DO  - 10.3389/fimmu.2017.01203
PY  - 2017///
SN  - 1664-3224
TI  - TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
T2  - Frontiers in Immunology
UR  - http://dx.doi.org/10.3389/fimmu.2017.01203
UR  - http://hdl.handle.net/10044/1/56793
VL  - 8
ER  -
Download